Entyvio 300 mg (Vedolizumab)

What is Entyvio (Vedolizumab) 300 mg?

Entyvio (Vedolizumab) 300 mg is a monoclonal antibody used for the treatment of inflammatory bowel diseases, including ulcerative colitis (UC) and Crohn’s disease (CD). Manufactured by Takeda Pharmaceuticals, Entyvio is designed to reduce gut inflammation by targeting specific proteins involved in the immune response. It is administered intravenously and is typically prescribed for patients who have not responded well to conventional treatments or TNF inhibitors.

How Does Entyvio Work?

Entyvio contains Vedolizumab, an integrin receptor antagonist that works by selectively blocking α4β7 integrins in the gut. This mechanism prevents white blood cells from migrating to inflamed intestinal tissues, thereby reducing inflammation and associated symptoms. Unlike systemic immunosuppressants, Entyvio mainly affects the gastrointestinal tract, leading to fewer systemic side effects.

Indications: What Conditions Does Entyvio Treat?

Entyvio (Vedolizumab) 300 mg is primarily used to treat:

• Ulcerative Colitis (UC): A chronic inflammatory condition affecting the colon and rectum, leading to symptoms like diarrhea, rectal bleeding, and abdominal pain.
• Crohn’s Disease (CD): A type of inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, causing symptoms like severe diarrhea, fatigue, weight loss, and malnutrition.

Entyvio is prescribed for patients who have not responded to corticosteroids, immunomodulators, or TNF blockers like Infliximab or Adalimumab.

Dosage & Administration: How to Use Entyvio 300 mg?

• Formulation: 300 mg powder for concentrate solution (IV infusion)
• Administration Route: Intravenous (IV) infusion
• Recommended Dosage:
  • Initial dose: 300 mg at weeks 0, 2, and 6
  • Maintenance dose: 300 mg every 8 weeks
• Infusion Duration: Approximately 30 minutes under the supervision of a healthcare professional
• Precautions: Do not administer as a rapid IV push or bolus injection.

Side Effects of Entyvio

Although Entyvio is well tolerated by most patients, some potential side effects include:

• Common Side Effects: Headache, nausea, joint pain, fever, fatigue, and infections.
• Serious Side Effects: Progressive multifocal leukoencephalopathy (PML), severe allergic reactions, or liver dysfunction. If any of these occur, consult a healthcare provider immediately.

Why Choose Entyvio (Vedolizumab) Over Other IBD Treatments?

• Gut-specific action: Unlike systemic immunosuppressants, Entyvio mainly targets the GI tract, reducing systemic side effects.
• Effective for refractory cases: Suitable for patients who have failed other biologics, such as TNF inhibitors.
• Long-term remission: Clinical studies show that Entyvio helps maintain long-term remission in both UC and CD patients.

Precautions & Warnings

• Not recommended for patients with active infections.
• Patients should be monitored for signs of progressive multifocal leukoencephalopathy (PML).
• Live vaccines should be avoided while on Entyvio treatment.
• Use with caution in pregnant or breastfeeding women.